CAMBRIDGE, Mass., Nov. 29, 2017 — Codiak BioSciences, Inc., the leading exosome therapeutics company, today announced the closing of a Series C financing round of $76.5 million. In its two years as a company Codiak’s funding totals $168.5 million. Codiak’s initial investors, including ARCH Venture Partners, Flagship Pioneering, Fidelity Management and Research Company, the Alaska Permanent Fund, and Alexandria Venture Investments, participated in the Series C round, and were joined by new investors, including Qatar Investment Authority, Boxer Capital of the Tavistock Group, Sirona Capital, EcoR1 Capital, and Casdin Capital.
Ncardia and Evotec Enter Licencing Agreement for Disease Modelling Using iPS Cells
December 04, 2017, GOSSELIES, Belgium—Ncardia, a leader in standardised, validated iPSC assays for safety, phenotypic screening and disease modeling, announced today that they entered into a global non-exclusive IP licensing agreement with Evotec (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809). The financial terms of the agreements are not disclosed. [Read more…]
Does Your Stem Cell Market Intelligence Utilize Futuristic Techniques?
2017 has never seen more opportunity for analysis of data, as the total global amount of data is now estimated to be 1.2 zettabytes.
Therefore, techniques for managing analysis of data must dynamically evolve.
While you may not understand the precise meaning of research terms such as meta-analysis, algorithmic analysis, or predictive trend analysis, it is important to ask yourself, are you embracing new and evolving methods for sourcing market data?
Futuristic (Definition): “Having or involving very modern technology or design”
Whether you are conducting your own market research or outsourcing it to a third-party, you should get clear answers to the following: [Read more…]
Avalon GloboCare Acquires Leading Beijing Exosome Technology Company
Avalon Forms Subsidiary U.S. Company, GenExosome Technologies Inc., for the Global Advancement of Exosome Technology for Diagnosis and Treatment of Diseases
FREEHOLD, NJ–(October 30, 2017) – Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that its majority-owned subsidiary GenExosome Technologies Inc. (GenExosome) acquired 100% of the outstanding capital stock of Beijing Jieteng (Beijing GenExosome) Biotech Co. Ltd. Concurrently, GenExosome entered into and closed an Asset Purchase Agreement with Dr. Yu Zhou, CEO of GenExosome Beijing, pursuant to which GenExosome acquired all assets, including all intellectual property, patents and patent applications held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies. Additional details of the transaction are available in the Company’s form 8-K filed with the Securities & Exchange Commission on October 27, 2017, and is available at www.sec.gov.
[Read more…]
ACEA Biosciences and Ncardia Partner to Provide Solutions for Cardiac Drug Discovery and Cardiac Safety Assessment
- « Previous Page
- 1
- …
- 202
- 203
- 204
- 205
- 206
- …
- 313
- Next Page »